Cardiac disease and arrhythmogeneration: Mechanistic insights from mouse models

Lois Choy a, Jie Ming Yeo b, Vivian Tse c, Shing Po Chan a, Gary Tse a,*

a School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
b School of Medicine, Imperial College London, SW7 2AZ, UK
c Department of Physiology, McGill University, Canada

A R T I C L E   I N F O

Article history:
Received 8 March 2016
Accepted 2 May 2016
Available online 14 May 2016

Keywords:
Mouse model
Cardiac arrhythmia
Cardiomyopathy
Ion channelopathy
Conduction
Repolarization

A B S T R A C T

The mouse is the second mammalian species, after the human, in which substantial amount of the genomic information has been analyzed. With advances in transgenic technology, mutagenesis is now much easier to carry out in mice. Consequently, an increasing number of transgenic mouse systems have been generated for the study of cardiac arrhythmias in ion channelopathies and cardiomyopathies. Mouse hearts are also amenable to physical manipulation such as coronary artery ligation and transverse aortic constriction to induce heart failure, radiofrequency ablation of the AV node to model complete AV block and even implantation of a miniature pacemaker to induce cardiac dysynchrony. Last but not least, pharmacological models, such as gap junction modulators, that may be exert therapeutic effects in other cardiac diseases. In this article, we examine these in turn, demonstrating that primary inherited arrhythmic syndromes are now recognized to be more complex than abnormality in a particular ion channel, involving alterations in gene expression and structural remodelling. Conversely, in cardiomyopathies and heart failure, mutations in ion channels and proteins have been identified as underlying causes, and electrophysiological remodelling are recognized pathological features. Transgenic techniques causing mutagenesis in mice are extremely powerful in dissecting the relative contributions of different genes play in producing disease phenotypes. Mouse models can serve as useful systems in which to explore how protein defects contribute to arrhythmias and direct future therapy.

© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

The mouse is the second mammalian species, after the human [12], in which substantial amount of the genomic information has been analyzed [13]. With advances in transgenic technology [14], mutagenesis is now much easier to carry out in mice [15]. Consequently, an increasing number of transgenic mouse systems have been generated for the study of cardiac arrhythmias [16,17]. These models can be loosely divided into ion channelopathies with minimal structural abnormalities, and those of structural heart disease. The former group includes catecholaminergic polymorphic ventricular tachycardia (CPVT) [18], the long [19] and short QT syndromes (LQTS and SQTS), and Brugada syndrome (BrS) [20]. The latter group includes several types of cardiomyopathies, such as arrhythmogenic right ventricular dysplasia (ARVD) [21], dilated cardiomyopathy (DCM) [22] and hypertrophic cardiomyopathy (HCM) [23]. However, now it is much clearer that structural alterations are found in ion channelopathies; for example, myocardial fibrosis is observed in BrS [24–26], DCM and non-compaction cardiomyopathy features are found in cardiac ryanodine receptor 2 mutation that is classically observed in CPVT [27]. Conversely, cardiomyopathy has been associated with ion channel mutations, as exemplified by sodium channel mutation in DCM [28]. Thus, these categories inevitably contain some overlap. As previously suggested, a better classification of cardiomyopathy includes additional subtypes affecting the cytoskeleton, desmosome, sarcomere and ion channels [29]. Some authors have asserted that this classification is too complex for clinical use, proposing instead a “MOGES” classification based on “morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E) including genetic defect or underlying disease/substrate, and the functional status (S) of the disease” [30]. Atrial fibrillation is a particularly complex disease, involving an interplay between electrical and structural remodelling, autonomic imbalance, alterations in calcium handling and genetic factors [31]. Mouse studies have illustrated the importance of abnormal metabolism in the initiation of paroxysmal atrial fibrillation and its progression to persistent and permanent forms [32], and shed light on the electrophysiological abnormalities predisposing to arrhythmias [33], but will not be discussed further in this review.
Non-genetic mouse models have also been used for the study of human cardiovascular conditions and associated arrhythmic properties [34]. Physical models include myocardial infarction produced by coronary artery ligation [35], hypertrophy and heart failure by transverse aortic constriction [36], complete AV block model by radiofrequency ablation of the AV node [37] and cardiac dys synchrony model by implantation of a miniature pacemaker tailored to mouse hearts [38]. In contrast, pharmacological models include the use of cardiac glycodies [39], hypoxia [40], myocardial sensizers [41] such as chloroform [42,43] and alterations in electrolyte concentrations, for example, potassium [44]. Cardiac toxins such as ethanol [45] and doxorubicin [46] have been used for modelling heart failure [47]. The different types of models are summarized in Fig. 1. In the next section, the advantages and disadvantages of mouse models, and comparisons between human cardiac physiology and mouse cardiac physiology will be discussed. The current understanding of each pathology, focusing on how mouse models have aided understanding, will then be reviewed in turn.

2. Advantages and disadvantages of mouse models

Several reasons justify the use of mice to study of human arrhythmia conditions. Firstly, 99% of mouse genes have a homologue in the human genome [13]. Secondly, both species have a similar set of ion channel genes [48]. Thirdly, the vast majority of these ion channel genes have nearly identical sequence homology in both species [49]. Fourthly, these genes have similar expression patterns, and their protein products show similar structural, electrophysiological [50] and pharmacological properties [48]. Finally, the same mutation in ion channel genes can often produce similar phenotypes in both species. For example, genetically engineered mice with altered potassium channel expression show prolonged ventricular action potential durations (APDs), prolonged electrocardiographic QT intervals and increased arrhythmogenicity, closely recapitulating the findings in the corresponding human conditions [51]. There are also advantages of using mice. The first relates to their vulnerability to arrhythmias. The mouse heart is electrically more stable than the human heart because of its small size, and spontaneous ventricular arrhythmias are therefore less likely to occur [49]. This means a smaller number of mice are lost due to unwanted lethal arrhythmias, potentially saving costs. The second relates to the relative ease of defibrillation. Arrhythmias are easier to reverse in mice than in larger species, making them invaluable for the evaluation of the effectiveness of antiarrhythmic drugs. However, caution must be taken because efficacy could be overestimated.

3. Comparisons between human and mouse cardiac electrophysiology

Mouse hearts are similar to human hearts in many respects, making them invaluable as model systems for the study of human arrhythmia syndromes. Firstly, the SA and AV nodes as well as the His-Purkinje system are structurally similar [52]. Secondly, the same patterns of depolarization and repolarization are observed in both species, with depolarization spreading from endocardium to epicardium and from apex to base, and repolarization from epicardium to endocardium and from base to apex [53]. Thirdly, the transmural conduction velocities (CVs) are nearly identical in mouse and human hearts [53]. Fourthly, apex-base and endocardium-epicardium repolarization gradients are present in both species [54]. Finally, the upstroke of the action potential in both mice and humans is attributed to $I_{Kr}$, making mouse hearts especially suitable for studying changes in CV [55]. Readers who are interested in the electrophysiological mechanisms of arrhythmogenesis are directed to these review articles [56–58].

However, it must also be recognized that mice do show some important differences in their cardiac electrophysiology [51,53,59]. Firstly, the basal heart rate in the mouse is around 600 bpm, which is ten times greater than that observed in the human [60]. Secondly, the morphology of the mouse and human ventricular action potentials is different, with the mouse ventricular action potential having a shorter duration and lacking a plateau phase [61]. This has been attributed to different expression levels of repolarizing potassium channels. Thus, $I_{Kr}$ is the major repolarization current with $I_{Ks}$ and $I_{K1}$ having a diminished role in mice [62], whereas $I_{Kr}$ and $I_{K1}$ are the major repolarization currents in humans [63]. Additional differences between mouse and human electrophysiology lead to difficulties in extrapolating data obtained from mice to humans and interpreting the mouse electrocardiogram [64]. Other species such as guinea pigs [65–71] and rabbits [72,73] may be better models for studying cardiac repolarization, as their ion currents are similar to those found used by human hearts.

The critical mass hypothesis posited that heart size must be sufficiently large to support fibrillation [74]. Because the wavelength of the excitation, given by ERP x CV, must be smaller than the available path length to allow re-entry [75], mouse hearts were originally thought to be too small to sustain re-entrant pathways. However, reconstruction of activation pattern [64] and mapping studies [19,76,77] have both shown that re-entry can take place. Bearing these limitations in mind, mouse models have provided significant advances in our understanding of cardiac electrophysiology. It is made possible by monophasic action potential (MAP) and bipolar electrogram (BEG) techniques to examine local activation and repolarization patterns [78–81]. Fig. 2 shows an experimental setup for recording left ventricular epicardial MAPs from isolated, Langendorff-perfused mouse hearts during right ventricular pacing. The study of congenital ion channelopathies has provided much insights into the general mechanisms by which disturbances in action potential conduction and repolarization generate arrhythmias, whereas that of heart failure and atrial fibrillation have identified pathological processes underlying disease progression with time and age [82]. These conditions will be discussed in turn.

4. Catecholaminergic polymorphic ventricular tachycardia (CPVT)

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited, cardiac ion channelopathy characterized by adrenaline-
driven ventricular arrhythmias [83]. Clinically it manifests frequently as bidirectional ventricular tachycardia (VT), which is inducible by exercise stress testing [84,85]. Other presentations include polymorphic VT and survivors of cardiac arrest [85]. An autosomal dominant form, CPVT1, was first found to be associated with mutations in the gene encoding for the cardiac ryanodine receptor 2 (RyR2), which releases calcium from the sarcoplasmic reticulum [86]. To date, some 150 mutations in RyR2 have been implicated in CPVT [85]. Recently, a large genomic deletion of human cardiac RyR2 gene, resulting from in-frame deletions of exon-3 (Ex3-del), has been detected in several, unrelated families [27,87–89]. The proposed mechanism of arrhythmogenesis in CPVT has traditionally been delayed afterdepolarization (DAD) phenomena leading to triggered activity (Fig. 3) [90]. This has been attributed to a leaky RyR2 leading to calcium release [91]. However, this mechanistic scheme is inadequate for arrhythmias due to loss-of-function RyR2 mutations, for which murine studies have provided much insight into the underlying physiological mechanisms [92]. CPVT2, an autosomal recessive form, is associated with missense mutations of the gene encoding for calsequestrin 2 (CASQ2), a calcium-binding protein of the sarcoplasmic reticulum [93,94]. Affected individuals were homozygous for the D307H missense mutation [93,94]. Interestingly, three other missense mutations in CASQ2 have been described in particular severe forms of CPVT, with possible autosomal dominant or oligogenic inheritance [95].

In mice, several gain-of-function mutations in RyR2 have been generated, shedding light onto the molecular mechanisms of arrhythmogenesis. Heterozygous knock-in mice carrying the RyR2 (R4496C) mutation shows increased calcium sensitivity of RyR2, leading to diastolic calcium release [96]. Interestingly, experiments in single cells from this system showed that increasing the sarcoplasmic reticulum calcium overload alone is sufficient to induce DAD activity through activation of the sodium–calcium exchanger (NCX) [97]. This took place even in an absence of beta adrenergic stimulation [97]. In homozygous RyR2-P2328S mice, abnormal calcium handling has been associated with reduced CVs, predisposing the hearts to spontaneous ventricular arrhythmias [98]. Studies using isolated myocytes showed that the abnormal functions of RyR2 have been rescued by increasing the affinity of calmodulin to RyR2, which reduced the frequency of DADs and triggered activity [99]. In contrast, mouse models for loss-of-function RyR2 mutation can be exemplified by RyR2-A4860G heterozygotes [92]. Isolated myocytes from these mice showed a reduced amplitude of calcium release during systole, leading to calcium overload of the sarcoplasmic reticulum [92]. This in turn caused random bursts of prolonged calcium release, activation of NCX with consequent early after-depolarization (EAD) phenomena. Furthermore, heterozygous Ex3-del mice (Ex3-del+/−) modelling the corresponding human condition failed to show susceptibility to CPVT [100]. Nevertheless, cardiac specific, conditional knockout of the wild-type RyR2 allele in Ex3-del+/− mice led to bradycardia and sudden death [100], closely recapitulating the findings observed in humans. This would suggest there are variations in the arrhythmic phenotype. Finally, genetically modified mice bearing CASQ2 mutation showed decreased refractoriness of the RyR leading to spontaneous diastolic calcium release, and hence the development of DADs [101].

In summary, the above mouse models implicate abnormal calcium handling as a predominant mechanism underlying arrhythmogenesis in CPVT. This in turn results in an inward current by activation of the NCX, and in turn to EADs or DADs, which can induce triggered activity. Abnormal calcium handling may also lead to reduced CV of action potential propagation, additionally serving as a substrate for circus re-entry (Fig. 4).

5. Long QT syndromes (LQTS)

Long QT syndromes (LQTS) refers to a group of disorders characterized by a prolonged QT interval of ≥450 ms on the electrocardiogram (ECG), with congenital or acquired causes. The underlying electrophysiology involves either reduced repolarizing currents or increased depolarizing currents. Congenital LQTS has two hereditary variants: Romano–Ward syndrome is inherited in an autosomal dominant manner, and Jervell and Lange–Nielsen (JLN) syndrome shows autosomal recessive inheritance associated with congenital deafness [102]. Thirteen LQTS subtypes have been identified thus far. LQTS 1 (KCNQ1), 2 (KCNH2), 5 (KCNE1), 6 (KCNE2), 7 (KCNJ2) and 13 (KCNJ5) are caused by loss-of-function mutations in genes encoding for the different potassium channels. LQTS 3 (SCN5A) and 10 (SCN4B) are caused by gain-of-
function mutations in genes for sodium channel subunits. LQTS 8 (CACNA1C), called Timothy syndrome, is caused by gain-of-function mutations in the L-type calcium channel. LQT 4 (ANKB), 9 (CAV3), 11 (AKAP9) and 12 (SNTA1) are caused by mutations in other supporting proteins. Acquired causes of LQTS are much more common than congenital syndromes. This is exemplified by hypokalaemia, which is the most common electrolyte abnormality encountered in clinical practice. A mouse pharmacological model of experimental hypokalaemia has demonstrated the following electrophysiological mechanisms: APDs are prolonged, predisposing to EADs and therefore triggered activity (Fig. 5) [44,103]. This prolongation preferentially occurs at the epicardium compared to the endocardium, leading to a reversal of the transmural repolarization gradient [44]. This in combination with reduced refractory periods [104], produced a favourable substrate for re-entrant arrhythmias that can readily be induced by programmed electrical stimulation. Moreover, altered cardiac dynamics, particularly the onset of APD alternans, attributed to increased steepness of action potential restitution, also contribute to re-entrant substrates (Fig. 6) [57,105]. It was shown that loss of gap junction function paradoxically exerted anti-arrhythmic effects, by reversing changes in refractory periods despite leaving APD and CV restitution unaffected [103,105]. Modulation of gap junctions may therefore be a viable therapeutic strategy for anti-arrhythmic therapy [106–109].

6. Short QT syndromes (SQTS)

Short QT syndrome is a group of heterogeneous conditions characterized by an abbreviated QT interval (QTc < 350ms). It causes an increased risk of atrial and ventricular arrhythmias, in particular ventricular fibrillation, thereby predisposing to sudden cardiac death. The shortening of QT interval could be contributed by an increased activity of repolarizing current, and reduced activity of depolarizing currents. Six genetic subtypes of SQTS have been identified thus far. Gain-of-function mutations in the potassium channel genes, KCNH2, KCNQ1 [110,111] and KCNJ2 [112] are found in SQT1, 2 and 3. By contrast, loss-of-function mutations in L-type calcium channel subunits, CACNA1C, CACNB2 and CACNA2D1, are found in SQT4, 5 and 6, respectively [113]. Interestingly, altered cardiac metabolism can also lead to a SQT phenotype, as exemplified by mice treated with mildronate, which resulted in low carnitine and shortened QT intervals [114]. The common electrophysiological abnormality involves shortened APD, which reduces the excitation wavelength and thereby predisposing to circus-type re-entry [58]. Unlike the long QT syndromes, abnormal APD restitution leading to alternans formation, which involves APD prolongation, is unlikely to be a contributing factor in arrhythmogenesis [57].

7. Brugada syndrome (BrS)

In Brugada syndrome, there is loss-of-function mutations in the SCN5A gene, predisposing affected individuals to ventricular arrhythmias and sudden death [115]. There has been considerable debate on the mechanisms of arrhythmogenesis in BrS. The leading theories are the depolarization and repolarization hypotheses [116]. The depolarization hypothesis proposes that mild structural abnormalities leading to conduction disturbances, which would predispose to circus-type re-entry. By contrast, the repolarization hypothesis depends on transmural dispersion of repolarization between endocardium and epicardium in the right ventricular outflow tract (RVOT). Experiments performed on mouse models have shed some light on the underlying mechanisms. Thus, heterozygous targeted disruption of Scn5a (Scn5a<sup>+/−</sup>) mice showed conduction abnormalities associated with fibrosis in the right ventricle [117]. Adult mice heterozygous for a mutation associated with BrS (Scn5a<sup>1798insD</sup>/−) showed reduced CVs in the RVOT [118], and those possessing the SCN5a<sup>G140R</sup> mutation showed slowed conduction, shortened APDs despite prolonged refractory periods associated with mild interstitial fibrosis [119]. This would suggest contributions from both depolarization and repolarization abnormalities to the arrhythmic phenotype. Reduced sodium current can also arise from dysfunction of other proteins, such as the desmosomal component plakophilin-2. Patients with missense mutations of this protein show a reduced number of sodium channels at the intercalated disc associated with a Brugada phenotype. Interestingly, mouse hearts with plakophilin-2 nonsense mutations show a phenotype that is more consistent with ARVD, as described below [120]. This in turn suggests that although both ARVD and BrS are primarily right ventricular diseases, there is a phenotypical spectrum with decreasing severity of structural abnormalities away from ARVD towards BrS.

8. Arrhythmogenic right ventricular dysplasia (ARVD)

Arrhythmogenic right ventricular dysplasia (ARVD) is a primary cardiomyopathy characterized by fibro-fatty replacement of the right ventricular myocardium, predisposing affected individuals, particularly in young adults and athletes, to ventricular arrhythmias and sudden cardiac death [121]. The disease progresses to ventricular wall thinning and development of aneurysms [122]. Approximately 50% of the patients have defects in their desmosomal components [123]. Desmosomes consist of cadherins, armadillo proteins (which include plakoglobin and plakophilin 2, PKP2) and desmoplakin, which links this complex to desmin in the intermediate filament [124]. The culprit for the remaining
50% are elusive, but mouse models have provided much insight into the different proteins affected. Inhibitor of apoptosis-stimulating protein of p53 (IAP) is a protein expressed in intercalated discs, interacting with desmoplakin [125] and its deficiency was shown to induce features of ARVD in mice [125]. Rho-kinase inhibition in the developing mouse heart (SM22α-restricted) show similar physical findings [126]. Although traditionally recognized as a predominant right ventricular disease, left-dominant and biventricular involvement has been described [127]. Mouse models have advanced our understanding, in particular implicating desmoplakin deficiency as a cause in left-ventricular and biventricular dominant forms [128], supporting similar findings observed in humans [129].

In humans, recent studies have implicated exercise and endurance training as precipitants or triggers of arrhythmias [130,131]. Exercise trained but not sedentary mice [120]. This would suggest an unmasking of an otherwise quiescent arrhythmic phenotype inducible by exercise. Together, both clinical and mouse studies provide evidence that exercise restriction prevent the occurrence of ventricular arrhythmias in ARVD patients [132].

Interestingly, DCM has been associated with reduced SCN5a expression [138]. Thus, in transgenic mice that ectopically express the transcriptional repressor Snail, there was a severe DCM phenotype together with reduced sodium current and conduction slowing without changes in intercellular coupling. The mechanism of arrhythmia here may be circus-type re-entry, which requires conduction slowing. Moreover, mice with the D1275N mutation in SCN5a showed features of DCM, resembling those of DCM in humans [133]. It predisposes affected individuals to ventricular arrhythmias and sudden death. Only 30% of DCM cases are familial [133]. To date, two X-linked and 31 autosomal genetic mutations have been identified as the causes of DCM [134,135]. Often these are proteins that are responsible for maintaining structural integrity of the cardiomyocyte, such as myosin heavy chain (MHC), myosin-binding protein C (MyBP-Ct/t), develop severe dilated cardiomyopathy, implicating desmoplakin deletion mutation [125] and its dependence as the causes of DCM [136,137].

As viral infections by enteroviruses and adenovirus, which result in myocarditis and subsequently DCM [136]. Mouse models have been useful in elucidating the ion channel abnormalities and electrophysiological mechanisms underlying arrhythmogenesis in this condition. For example, homozygous mutant mice expressing a truncated form of myosin-binding protein C (MyBP-Ct) develop severe dilated cardiomyopathy, exhibited extensive cardiac fibrosis associated with inducible ventricular tachycardia (AT) despite surprisingly normal conduction and refractoriness [137].

In other mouse model, where mice overexpressing dominant-negative neuron-restrictive silencer factor (NRSF), a transcriptional regulator of myosin, developed a DCM phenotype [142]. These mice showed increased expression of I_L and I_C,T, which are usually expressed in pacemaker cells, suggesting that increased automaticity may also be an underlying arrhythmogenic mechanism in DCM. In cardiomyocytes, the cytoskeleton is in close association with the nuclear envelope, aided by inner nuclear membrane proteins called lamins. Heterozygous lamin

9. Dilated cardiomyopathy (DCM)

Dilated cardiomyopathy is a type of primary cardiac muscle disorder characterized by increased ventricular mass and dilatation associated with impaired mechanical function [133]. It predisposes affected individuals to ventricular arrhythmias and sudden death. Only 30% of DCM cases are familial [133]. To date, two X-linked and 31 autosomal genetic mutations have been identified as the causes of DCM [134,135]. Often these are proteins that are responsible for maintaining structural integrity of the cardiomyocyte, such as myosin heavy chain (MHC), myosin-binding protein C, alpha tropomyosin, and titin, which is the largest protein identified thus far. Other causes include environmental factors, such as viral infections by enteroviruses and adenovirus, which result in myocarditis and subsequently DCM [136].
knockout (Lmna^{−/−}) mice showed DCM phenotype associated with increased susceptibility to AV nodal disease as well as ventricular tachycardia [143].

10. Hypertrophic cardiomyopathy (HCM)

Hypertrophic cardiomyopathy is the commonest inherited cardiac disease characterized by a non-dilated, hypertrophied left ventricle without other causes of hypertrophy, such as storage, infiltrative disease or pressure overload, being observed [144]. Its genetics are less heterogeneous than DCM, as mutations in the genes that encode for the myosin heavy chain, myosin binding protein C and troponin T are responsible for about 75% of all inherited HCMs [145]. Heterozygous MyBP-C^{−/+} mice showed a mild HCM and inducible ventricular tachycardia after pharmacological stress with isoproterenol [137]. The duration of the VT is less than the homozygous MyBP-C^{−/−} mice showing a severe DCM phenotype described above. Like DCM, in mice bearing the MHC mutation its genetics are less heterogeneous than DCM, as mutations in the genes that encode for the myosin heavy chain, myosin binding protein C and troponin T are responsible for about 75% of all inherited HCMs [145]. Heterozygous MyBP-C^{−/+} mice showed a mild HCM and inducible ventricular tachycardia after pharmacological stress with isoproterenol [137]. The duration of the VT is less than the homozygous MyBP-C^{−/−} mice showing a severe DCM phenotype described above. Like DCM, in mice bearing the MHC mutation its genetics are less heterogeneous than DCM, as mutations in the genes that encode for the myosin heavy chain, myosin binding protein C and troponin T are responsible for about 75% of all inherited HCMs [145].

11. Heart failure

Heart failure is a significant burden on our healthcare system, and represents a common pathway of many aetiologies with an abysmal clinical outcome [150]. It is characterized by structural abnormalities of left ventricular dysfunction and dilatation, a compensatory rise in systemic vascular resistance secondary to activation of neurohumoral pathways [151], inflammation and metabolic adaptations to substrate utilization [152]. The net effect is comprised cardiac contractility and the inability to meet metabolic demands of peripheral tissues [153]. Cardiac dysynchrony is a feature observed in heart failure, referring to the disruption in both temporal and mechanical coordination between the contractive motions of different cardiac compartments. It can be divided into atrioventricular, interventricular and intraventricular dysynchrony.

The commonest heart failure model involves surgery intervention. Generation of these models allow the different stages of heart failure to be examined. Coronary artery ligation mimics myocardial infarction [35,154], producing scarring of the myocardium followed by dilatation of the ventricle. Novel methods of coronary artery ligation have recently been devised to model ischaemia–reperfusion [155,156], which would be ideal for studying arrhythmias associated with this phenomenon. In contrast, transverse aortic banding simulating pressure overload from aortic stenosis or hypertension triggers hypertrophic response to that similarly observed in humans [36,157]. Non-invasive imaging modalities such as strain-based modelling revealed areas of dysynchrony when there is no overt heart failure [158]. This supports the notion that regional, as opposed to global, stress is induced by increased afterload. The risk of ventricular arrhythmias is reduced when intraventricular dysynchrony improves in humans [159]. Mouse models will be ideal for studying arrhythmias associated with this phenomenon.

12. AV block

AV block refers to a group of disorders characterized by partial or complete interruption of impulse transmission from the atria to the ventricles. Depending on the extent of impulse interruption, it can be classified into first, second and third-degree, each with characteristic appearance on the electrocardiogram. Approximately 50% of patients with AV block have idiopathic fibrosis and sclerosis of the conduction system, 40% have ischaemic heart disease and the remaining minority of cases can be attributed to valvular disease, increased vagal tone and congenital bradycardia syndromes [164,165]. This condition can also be caused by drugs, such as fangolomod, pro-drug of a S1P-R modulator licensed for multiple sclerosis [166]. Patients suffering from complete atrioventricular block (CAVB) have an increased risk of sudden cardiac death, potentially from QT prolongation and VT. Mouse models have provided much insight of the electrophysiological mechanisms underlying idiopathic AV block. It is now recognized that several proteins are responsible for the maintenance of AV conduction [167], such as T-type calcium channels [168], L-type calcium channels [169], HCN channels [170], and Sphingosine-1-phosphate receptor [171].

Mice with radiofrequency ablation of the AV node exhibited electrophysiological modelling preceded structural remodelling, which were associated with increased QT intervals and occurrence of polymorphic VT [172]. Thus, K_{ATP} channels were downregulated with a consequent reduction in the transient outward potassium current. These changes were followed by biventricular hypertrophy and heart failure, as reflected in transcriptional changes such as rise in α-actin, β-MHC and B-type natriuretic peptide and fall in SERCA2 expression. Transgenic mouse models have also provided additional insight. Mice with deletion of Ca,3,1, which encodes for the α-subunit of the T-type calcium channel, was used in combination with radiofrequency AV node ablation [173]. These mice showed hypertrophic remodeling after AV block and were more prone to bradycardia-related ventricular arrhythmias.

Current treatment of AV block is by pacemaker implantation. With consideration of the shortcomings of electronic pacemakers, genetic manipulation of specific ion channels for biological pacemaker development has been an area of intense research. Thus, non-viral gene transfer with poloxamine nanosphere as the gene delivery system was used to induce overexpression of the pacemaker current-generating channel HCN2 and β_{2}-adrenergic receptor (ADRB2), with the generation of functional biological pacemakers and improvement in life expectancy of mice with CAVB [37]. Recently, a S1P_{3} receptor antagonist (SPM–354) was found to restore sinus rhythm and reverse CAVB [174]. Stem cell therapy has also demonstrated promising results. Recently, brown adipose tissue (BAT)-derived cells were injected intramyocardially around the AV node, which full or partial recovery to sinus rhythm or second degree 2:1 block [175].

13. Conclusion

This article reviewed the different genetic and physical models of cardiovascular diseases, and explored how mouse models have contributed to our understanding of arrhythmogenesis in these conditions [1–9]. Primary inherited arrhythmogenic syndromes are now recognized to be more complex than abnormality in a particular ion channel, involving alterations in gene expression and structural remodelling [10,11]. Conversely, in cardiomyopathies and heart failure, mutations in ion whether particular alterations of gene expression represent adaptive or maladaptive responses [160,161]. Mutagenesis has been coupled with coronary artery ligation techniques to examine the propensity to arrhythmias. Thus, toll-like receptor 2 deficiency confers a protective effect against ventricular arrhythmias and reduces infarct size [162], whereas cardiac knockout of mitochondrial uncoupling protein 3 shows poorer ventricular function and larger infarct size compared to wild-type [163].
channels and proteins have been identified as underlying causes, and electrophysiological remodeling are recognized pathological features. Transgenic techniques causing mutagenesis in mice are extremely powerful in dissecting the relative contributions of different genes play in producing disease phenotypes. The importance of translational research cannot be overstated. As previously suggested, a better classification is myocardial disease involving abnormalities in one of the following cellular components: cytoskeleton, desmosome, sarcomere and ion channels [29]. Overlap syndromes between different cardiomyopathies are now increasingly recognized but are nevertheless uncommon in humans, and indeed rarer than individual cardiomyopathy occurring in isolation. Thus, overlapping features between DCM and HCM, ARVD and HCM, ARVD and DCM, and part-pastur myocardopathy (PPCM) and ARVD [176] have all been described. Mouse models can serve as useful systems in which to explore how protein defects contribute to arrhythmias and direct future therapy.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

GT was awarded a doctoral training award (DTA) from the Biotechnology and Biological Sciences Research Council (BBSRC) at the University of Cambridge.

References

[1] G. Tse, T.H. Lai, J.M. Yeo, V. Tse, S.H. Wong, Mechanisms of electrical activation and conduction in the gastrointestinal system: lessons from cardiac electrophysiology, Front Physiol, 2016.
[2] G. Tse, B. Sun, S.T. Wong, V. Tse, J.M. Yeo, Ventricular anti-arrhythmic effects of hypercalcaemia treatment in hyperkalcaemia, Langenförd-perfused mouse hearts, Biomed Rep, 2016.
[3] G. Tse, E.T. Lai, V. Tse, J.M. Yeo, Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus, J Diabetes Res, 2016.
[4] G. Tse, E.T. Lai, J.M. Yeo, B.P. Yan, Electrophysiological mechanisms of Bayés syndrome: insights from clinical and mouse studies, Front Physiol, 2016.
[5] G. Tse, Both transmural dispersion of repolarization and transmural dispersion of refractoriness are poor predictors of arrhythmogenicity: a role for the index of Cardiac Electrophysiological Balance (Q/QR)?, J Geriatr Cardiol, 2016.
[6] G. Tse, A. Ali, F. Alpendurada, S. Prasad, C.E. Raphael, V. Vassiliou, Tuberculous Constrictive Pericarditis, Res Cardiovasc Med 4 (4) (2015), e29614.
[7] G. Tse, (Tpeak-Tend)/QR and (Tpeak-Tend)/(QT x QRS): novel markers for predicting arrhythmic risk in Brugada syndrome, Europace, 2016.
[8] G. Tse, Novel conduction-repolarization indices for the stratification of arrhythmic risk, Geriatr Cardiol. (2016).
[9] G. Tse, B.P. Yan, Novel arrhythmic risk markers incorporating QRS dispersion: QRSd x (Tpeak-Tend) / (QRS and QRSd x (Tpeak-Tend) / (QT x QRS), Ann Noninvasive Electrocardiol, 2016.
[10] G. Tse, S.T. Wong, V. Tse, J.M. Yeo, Determination of action potential wavelength restitution in Scn5a−/− mouse hearts modelling human Brugada syndrome, J Physiol, 2016.
[11] G. Tse, S.T. Wong, V. Tse, J.M. Yeo, Depolarization vs. repolarization: what is the mechanism of ventricular arrhythmogenesis underlying sodium channel haploinsufficiency in mouse hearts? Acta Physiol (Oxf), (2016).
[12] International Human Genome Sequencing Consortium, Initial sequencing and analysis of the human genome, Nature 409 (2001) 860–921.
[13] Mouse Genome Sequencing Consortium, Initial sequencing and comparative analysis of the mouse genome, Nature 420 (2002) 520–562.
[14] C.J. Berul, Electrophysiological phenotyping in genetically engineered mice, Physiol Genomics 13 (2003) 207–216.
[15] S.L. Yong, Q.X. Wang, Animal models for cardiac arrhythmias, Methods Mol. Med. 129 (2006) 127–148.
[16] J. Tamargo, R. Caballero, L. Núñez, R. Gómez, M. Vaquero, E. Delpón, Genetically engineered mice as a model for studying cardiac arrhythmias, Front. Biosci. 12 (2007) 22–38.
[17] L.N. Sahir, M.J. Killeen, A.A. Grace, C.L. Huang, Ventricular arrhythmogenesis: Insights from murine models, Prog. Biophys. Mol. Biol. 98 (2008) 208–218.
[18] X.H. Welhens, S.E. Lehmann, F. Huang, J.A. Vest, S.R. Reiken, P.J. Mohler, et al., FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor function linked to exercise-induced sudden cardiac death, Cell 113 (2003) 829–840.
[19] G. Salama, B. London, Mouse models of long QT syndrome, J Physiol. 578 (2007) 43–53.
[51] J.M. Nerbonne, Studying cardiac arrhythmias in the mouse — a reasonable model for probing mechanisms? Trends Cardiovasc. Med. 14 (2004) 83–93.

[52] S. Rentzsch, D.M. Vaidya, H. Tamaddon, K. Degenhardt, D. Sasoon, G.E. Morley, et al., Visualization and functional characterization of the developing murine cardiac conduction system, Development 128 (2001) 1785–1792.

[53] G. Liu, J.B. Iden, K. Kovtunovych, R. Gulamhusein, H.J. Duff, M.K. Kavanagh, In vivo temporal and spatial assessment ofdepolarization and repolarization and the illus- trative murine T wave, J. Physiol. 555 (2004) 267–279.

[54] A. Antzelevitch, G.X. Yan, W. Shimizu, Transmural dispersion of repolarization and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome, J. Electrocardiol. 32 (1999) 158–165.

[55] G. Tse, S.S. Hoti, A.A. Grace, C.L. Huang, Ventricular arrhythmogenesisis following slowed conduction in heptanol-treated, Langendorff-perfused mouse hearts, J. Physiol. Sci. 62 (2012) 79–92.

[56] G. Tse, J.M. Yeo, Confounding abnormalities and ventricular arrhythmogenesis: the roles of sodium channels and gap junctions, J. Heart Vascul Res. 9 (2015) 75–82.

[57] G. Tse, S.T. Wong, V. T.Y. Lee, H.Y. Lin, J.M. Yeo, Cardiac dynamics: alternans and arrhythmogenesis, J. Arrhythm. (2016).

[58] G. Tse, Mechanisms of cardiac arrhythmias, J. Arrhythm. (2015) 75–81.

[59] J.M. Nerbonne, C.G. Nichols, T.L. Schwartz, D. Escande, Genetic manipulation of cardiac K+ channel function in mice: what have we learned, and where do we go from here? Circ. Res. 89 (2001) 946–956.

[60] B. London, Cardiac arrhythmias: from (transgenic) mice to men, J. Cardiovasc. Electrophysiol. 12 (2001) 1089–1091.

[61] L.C. Baker, B. London, B.R. Choi, G. Koren, G. Salama, Enhanced dispersion of repolarization and refractoriness in transgenic hearts promotes reentrant ventricular tachycardia, Circ. Res. 86 (2000) 396–407.

[62] L. Wang, S. Swirp, H. Duff, Age-dependent response of the electrocardiogram to K+ channel blockers in mice, Am. J. Physiol. Cell Physiol. 278 (2000) C670–C678.

[63] J.M. Nerbonne, Molecular basis of functional voltage-gated K+ channel diversity in O.E. Osadchii, Impact of hypokalemia on electromechanical window, excitation and restitution in a highly conserved region of CASQ2 is associated with autosomal reces-

[64] sive ventricular tachycardia, Circ. Res. 91 (2002) e21–e26.

[65] T. Nakajima, Y. Kaneko, Y. Taniguchi, R. Hayashi, T. Takiizawa, T. Suzuki, et al., The mechanism of catecholaminergic polymorphic ventricular tachycardia may be trig- gered activity due to delayed afterdepolarization, Eur. Heart J. 18 (1997) 530–531.

[66] J. Paavola, M. Vaitlans, P.J. Laitinen-Forsblom, M. Pasterнак, H. Swan, I. Tiikkanen, et al., Mutant rymyodine receptors in catectolaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves, Eur. Heart J. 28 (2007) 1135–1142.

[67] Y.T. Zhao, C.R. Valdivia, G.B. Gurrola, P.P. Powers, B.C. Willis, R.L. Moss, et al., Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses sodium channel function, Proc. Natl. Acad. Sci. U.S.A. 112 (2015) E1669–E1677.

[68] M. Fernandez-Velasco, A. Rueda, N. Rizzi, J.P. Benitah, B. Colombi, C. Napolitano, et al., Increased Ca2+ sensitivity of the rymyodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia, Circ. Res. 106 (2005) 2009–2019 (12 following 9).

[69] S. Sedej, F.R. Heinzel, S. Walther, N. Dbikova, P. Wajkula, J. Groborz, et al., Increased SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CAV1 mutation, J. Cardiovasc. Electrophysiol. 26 (2015) 1859–1866.

[70] W.E. Garry, The nature of fibrillary contraction of the heart: its relation to tissue mass and form, Am. J. Physiol. 33 (1914) 397–414.

[71] N. Wiener, A. Rosenbluth, The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle, Arch. Inst. Cardiol. Mex. 16 (1946) 205–265.

[72] L. Fabritz, M.G. Hoogendijk, B.P. Scicluna, S.C. van Amersfoorth, L. Fortmueller, S. T.J. Wu, S.F. Lin, J.N. Weiss, C.T. Ting, P.S. Chen, Two types of ventricular conduction velocity and suppressing discordant alternans during therapeutic hy-

[73] potension, Circ. Res. 89 (2001) 944–956.

[74] Y.C. Hsieh, J.C. Lin, C.Y. Hung, C.H. Li, S.F. Lin, H.I. Yeh, et al., Gap junction modification from electrograms, IEEE Trans. Biomed. Eng. 56 (2009) 1546–1555.

[75] N. Wiener, A. Rosenbluth, The mathematical formulation of the problem of conduction of impulses in a network of connected excitable elements, specifically in cardiac muscle, Arch. Inst. Cardiol. Mex. 16 (1946) 205–265.

[76] L. Venetucci, M. Denegri, C. Napolitano, S.G. Priori, Inherited calcium channelopathies in the pathophysiology of arrhythmias, Nat. Rev. Cardiol. 9 (2012) 561–575.

[77] S.G. Priori, C. Napolitano, M. Memmi, B. Colombi, F. Drago, M. Gasparini, et al., Clin- ical and molecular characterization of patients with catecholaminergic polymor-

[78] phic ventricular tachycardia, Circulation 106 (2002) 1797–1804.

[79] S.G. Priori, S.R. Chen, Inherited dysfunction of sarcolemaptic reticulum Ca2+ hand-

[80] ling and arrhythmogenesisis, Circ. Res. 108 (2011) 871–883.

[81] S.G. Priori, C. Napolitano, N. Tiso, M. Memmi, G. Vignati, R. Bloise, et al., Mutations in the cardiac ryanodine receptor gene (RYR2) underlie catecholaminergic polymor-

[82] phic ventricular tachycardia, Circulation 103 (2001) 196–200.

[83] R. Veeraraghavan, R.G. Gourdie, S. Poelzing, R.G. Gourdie, Old cogs, new tricks: a scaffolding role for connexin43 and a junctional role for sodium channels? FEBS Lett. 588 (2014) 1244–1248.
C. Bellocq, A.C. van Ginneken, C.R. Bezzina, M. Alders, D. Escande, M.M. Mannens, et al., Mutation in the KCNJQ1 gene leading to the short QT-interval syndrome, Circ. Res. 110 (2012) 2397.

R. Schimpf, C. Wieland, F. Gaita, C. Giustetto, M. Borggrefe, Short QT syndrome, Cardiovasc. Res. 67 (2005) 357–366.

S.G. Priori, S.V. Pandit, I. Rivolta, O. Berenfeld, E. Ronchetti, A. Dhamoon, et al., A novel form of short QT syndrome (SQTS) is caused by a mutation in the KCNJQ2 gene, Circ. Res. 96 (2005) 800–807.

A. Zanettevich, G.D. Polle-Vick, J.M. Cordeiro, O. Caisi, M.C. Sanguinetti, Y. Aiawza, et al., Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death, Circulation 115 (2007) 442–449.

J. Rousseel, F. Labarte, J. Thireau, F. Ferro, C. Farah, J. Roy, et al., Carcinine deficiency induces a short QT syndrome, Heart Rhythm. (2015).

Q. Chen, G.E. Kirsch, D. Zhang, R. Brugada, J. Brugada, P. Brugada, et al., Genetic basis and molecular mechanism for idiopathic ventricular fibrillation, Nature 392 (1998) 293–296.

A.A. Wildt, P.G. Postema, J.M. Diogo, S. Viskin, H. Morita, J.M. Fish, et al., The pathophysiological mechanism underlying Brugada syndrome: de polarization versus repolarization, J. Mol. Cell. Cardiol. 49 (2010) 543–553.

A.L. Leoni, B. Gavillet, J.S. Rouger, C. Marionneau, V. Probst, S. Souacarme, et al., Variable Na(+)/v.1.5 protein expression from the wild-type allele correlates with the penetrance of cardiac conduction disease in the Scn5a(+/-) mouse model, PloS ONE 5 (2010), e9298.

B.J. Boukens, M. Sylva, C. de Gier-de Vries, C.A. Remme, C.R. Bezzina, V.M. Christoffels, et al., Reduced sodium channel function unmasks residual embryonic slow conduction in the adult right ventricular outflow tract, Circ. Res. 113 (2013) 137–141.

P.A. Schweizer, T. Fink, P. Yamplowsky, C. Seyler, L. Fabritz, P. Kirchhof, et al., Generation and characterization of SCNSA loss-of-function mutant mice modeling Brugada syndrome and chagasic cardiomyopathy, Eur. Hear. J. 34 (2013) 850–860.

F.M. Cruz, D. Sanz-Rosa, M. Roche-Molina, J. Garcia-Prieto, J.M. Garcia-Ruiz, G. Pizarro, et al., Exercise triggers ARCV phenotype in mice expressing a disease-causing mutated version of human plakophilin-2, J. Am. Coll. Cardiol. 65 (2015) 1438–1450.

C. Basso, D. Corrado, F.J. Marcus, A. Nava, G. Thiene, Arrhythmogenic right ventricular dysplasia/cardiomyopathy, Lancet 373 (2009) 1280–1289.

C. Basso, G. Thiene, D. Corrado, A. Angiolin, A. Nava, M. Valente, Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 94 (1996) 983–991.

N. Protonotarios, A. Tsatsopoulos, Naxos disease and Carvalj syndrome: cardiaccancerous disorders that highlight the genetics and broaden the spect- rum of arrhythmogenic right ventricular cardiomyopathy. Cardiovasc. Pathol. 13 (2004) 185–194.

C. Jamora, E. Fuchs, Interacellular adhesion, signalling and the cytoskeleton, Nat. Cell Biol. 4 (2002) E101–E108.

M. Notari, Y. Hu, G. Sentudra, Z. Dedeci, M. Mu, L. Dupays, et al., JASP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy (ARVC)-induced sudden death, Proc. Natl. Acad. Sci. U.S.A. 112 (2015) E573–E581.

A. Ellawadny, K. Satoh, S. Sunamur, N. Kikuchi, K. Suzuki, T. Minami, et al., Rho-kinase inhibition during early cardiac development causes arrhythmogenic right ventricular cardiomyopathy in mice, Arterioscler. Thromb. Vasc. Biol. 35 (2015) 2172–2184.

S. Song, R. Gowdhry, P. de la Morena, D. Ward, L. Sensini, E. Seidman, et al., A genetic and protein characterization of families with arrhythmogenic right ventricular dys- plasia/cardiomyopathy provides novel insights into patterns of disease expression, Circulation 115 (2007) 1710–1720.

R.G. Hearse, P. De Caterin, A. Angiolin, A. Nava, M. Valente, Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 94 (1996) 983–991.

M. Norman, M. Simpson, J. Mogensen, A. Shaw, S. Hughes, P. Syrris, et al., Novel mutation in desmosplakin causes arrhythmogenic left ventricular cardiomyopathy, Circulation 112 (2005) 636–642.

C.A. James, A. Bhonsale, C. Tichnell, B. Murray, S.D. Russell, H. Tandri, et al., Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers, J. Am. Coll. Cardiol. 62 (2013) 1290–1297.

H. Heidbuchel, J. Hoogsteen, R. Fagard, L. Vanhees, H. Ector, R. Willems, et al., High prevalence of right ventricular involvement in endurance athletes with ventricular arrhythmias. Role of an electrophysiological study in risk stratification, Eur. Heart J. 24 (2003) 1473–1480.

P. Kirchhof, L. Fabritz, M. Zwiener, H. Witt, M. Schafers, S. Zellerhoff, et al., Genetic basis and molecular mechanism for idiopathic ventricular fibrillation, Nature 392 (1998) 293–296.
[168] M.E. Mangoni, A. Traboulsie, A.L. Leoni, B. Couette, L. Marger, K. Le Quang, et al., Bradycardia and slowing of the atrioventricular conduction in mice lacking Cav1.1/alpha1G T-type calcium channels, Circ. Res. 98 (2006) 1422–1430.
[169] L. Marger, P. Mesirca, J. Alig, A. Torrente, S. Dubel, B. Engeland, et al., Pacemaker activity and ionic currents in mouse atrioventricular node cells, Channels (Austin) 5 (2011) 241–250.
[170] M. Baruscotti, A. Bucchi, C. Visconi, G. Mandelli, G. Consalez, T. Gnecchi-Rusconi, et al., Deep bradycardia and heart block caused by inducible cardiac-specific knockout of the pacemaker channel gene Hcn4, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 1705–1710.
[171] E.E. Egom, P. Kruzliak, V. Rotrekl, M. Lei, The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue, J. Cell. Mol. Med. 19 (2015) 1729–1734.
[172] O. Bignolais, K.L. Quang, P. Naud, A. El Harchi, F. Briec, J. Piron, et al., Early ion-channel remodeling and arrhythmias precede hypertrophy in a mouse model of complete atrioventricular block, J. Mol. Cell. Cardiol. 51 (2011) 713–721.
[173] K. Le Quang, B. Benito, P. Naud, X.Y. Qi, Y.F. Shi, J.C. Tardif, et al., T-type calcium current contributes to escape automaticity and governs the occurrence of lethal arrhythmias after atrioventricular block in mice, Circ. Arrhythm. Electrophysiol. 6 (2013) 799–808.
[174] M.G. Sanna, K.P. Vincent, E. Repetto, N. Nhan, S.J. Brown, L. Abgaryan, et al., Bitopic S1P3 antagonist rescue from complete heart block: pharmacological and genetic evidence for direct S1P3 regulation of mouse cardiac conduction, Mol. Pharmacol. (2015).
[175] T. Takahashi, T. Nagai, M. Kanda, M.L. Liu, N. Kondo, A.T. Naito, et al., Regeneration of the cardiac conduction system by adipose tissue-derived stem cells, Circ. J. 79 (2015) 2703–2712.
[176] G. Tse, A. Ali, S.K. Prasad, V. Vassiliou, C.E. Raphael, Atypical case of post-partum cardiomyopathy: an overlap syndrome with arrhythmogenic right ventricular cardiomyopathy? BJR|case reports, 1, 2015 (20150182).